News Category: News and Insights

HUB Organoids Launches IntegriGut Screen: A Breakthrough Service Offering for Inflammatory Bowel Disease (IBD) Drug Discovery and Development

Utrecht, Netherlands – 25th Jan 2024 – HUB Organoids (HUB), a global leader and sole proprietor of patient-derived organoid technology for drug...

Tumors in Space Investigates Microgravity’s Impact on Cancer Using Patient-Derived HUB Organoids

Utrecht, November 30, 2023 – HUB Organoids B.V. participates in the second Tumors in Space European Space Agency parabolic flight which investigates...

HUB Organoids Announces New Corporate Strategy and Completes Transition from Foundation to Private Company

[Utrecht, July 18 2023] — HUB Organoids (HUB), the global leader in the field of patient-derived organoids, is excited to announce a...

HUB Organoids extends partnership with Molecular Devices to advance automated intestinal organoid screening technology

SAN JOSE, Calif., and UTRECHT, Netherlands, Feb. 13, 2023 – Molecular Devices, LLC., a leading provider of high-performance life science solutions, and...

HUB Organoids take their first parabolic flight!

FDA Modernization Act 2.0: We welcome the dawn of an organoid era

Imagine Reducing the Time to Identify a Drug

Patients with mutated KRAS (Kirsten rat sarcoma virus) gene account for around 30-50% of the population with colorectal cancer (CRC) and do...

Exclusive interview with Dr Carla Verissimo

Our Carla Verissimo, Head of Oncology II speaks about the current challenges of oncology drug development in this exclusive interview of the...

New PERSIST-SEQ program launched

2 September 2021, Utrecht (The Netherlands) - Hubrecht Organoid Technology (HUB) joins a new international consortium of academic and industrial leaders in...

Link revealed between HBV infection and liver cancer

HUB Organoids derived from patients with chronic hepatitis B show the first molecular signs of liver cancer. The molecular events that drive...